Morgan Stanley Hightlights PMI as Attractive Investment

Industry Insight by 2FIRSTS.ai
Jul.17.2023
Morgan Stanley Hightlights PMI as Attractive Investment
Morgan Stanley believes Philip Morris International is a top pick in the food and tobacco sectors, with an attractive risk-reward profile and potential for growth.

Morgan Stanley, has labeled Philip Morris International (PM) as a top pick in both the food and tobacco sectors. Analyst Pamela Kaufman has identified an attractive 4:1 risk-reward profile on the stock, suggesting that the recent pullback has created an enticing entry point for investors. 

 

One of the key reasons provided by Morgan Stanley to buy shares of Philip Morris International is the accelerating adoption of IQOS, a popular tobacco product, supported by the ILUMA rollout. Additionally, the Rapid Zyn growth in the U.S. presents an opportunity for international expansion. 

 

The company is also believed to have an appealing chance to penetrate the U.S. market for IQOS, while keeping investment spending under control. In terms of valuation, Philip Morris International is considered attractive compared to its peers in the Staples sector. The company's improving business mix, strong pricing power, U.S. expansion opportunity, and promising growth profile are factors that contribute to its appeal. 

 

Currently, PM is trading at a 14.5x NTM P/E ratio, which is 14% below its 10-year average of 16.8x. Furthermore, the stock is trading at a 37% discount compared to peers, a significant difference when compared to the average 20% discount observed over the past decade. PM is also available at a 26% discount to the S&P 500, unlike the usual 2% discount. On the balance sheet, Philip Morris International is expected to resume share buybacks and increase its dividend annually by 3%, providing additional incentives for investors. 

 

Morgan Stanley has given Philip Morris International a Buy rating, along with a price target of $118. This indicates the firm's confidence in the stock's potential to generate favorable returns. In the premarket session, shares of Philip Morris International were trading flat at $96.80. This is within the 52-week range of $82.85 to $105.62.

 

Reference:

 

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
Alabama SB9 advances: Senate committee clears bill to treat vaping like smoking in enclosed public places
Alabama SB9 advances: Senate committee clears bill to treat vaping like smoking in enclosed public places
Alabama’s Senate Bill 9 advanced after clearing the Senate Committee on Healthcare, moving to the full Alabama Senate for consideration. The proposal would update the state’s 2003 Clean Indoor Air Act by including e-cigarettes and other vaping devices under the same restrictions that apply to smoking in most enclosed public places.
Jan.22 by 2FIRSTS.ai
Oklahoma prisons to sell vapes and nicotine pouches to inmates in bid to curb contraband and violence
Oklahoma prisons to sell vapes and nicotine pouches to inmates in bid to curb contraband and violence
Oklahoma Department of Corrections (DOC) will launch a program allowing inmates to buy sealed disposable nicotine vapes and packs of nicotine pouches through prison commissaries. Tobacco has been banned in Oklahoma prisons for 10 years, and cigarettes and cigars will remain prohibited.
Feb.28
France’s ANSES warns vaping carries health risks, urges limiting e-cigarette use to smoking cessation
France’s ANSES warns vaping carries health risks, urges limiting e-cigarette use to smoking cessation
France’s National Agency for Food, Environmental and Occupational Health & Safety (ANSES) says vaping poses health risks because users inhale toxic or harmful substances, even if e-cigarettes are generally considered less harmful than cigarettes.
Feb.04 by 2FIRSTS.ai
Oregon Senate Passes Bill to Regulate Nicotine Pouches as Tobacco Products
Oregon Senate Passes Bill to Regulate Nicotine Pouches as Tobacco Products
The Oregon Senate voted 26–1 to pass Senate Bill 1571, a measure redefining tobacco products to include nicotine pouches and restricting their sale to individuals under 21.
Regulations
Feb.23